Health officials seek to expand victim intervention program
Health officials want to expand an intervention program that provides victims with critical resources as city and county officials also addressed violence as a public health crisis.
Atrium Health's hospital-based violence intervention program started seeing victims almost three years ago.
CMPD: Violent crime incidents down, but more victims in 2024
Staff members said they've seen significant results but need more resources to tackle the issue.
Project BOOST provides victims with resources, including mental health support, housing and drug treatment.
It started in 2022 and since then, Atrium Health officials said it's seen 270 victims of violence, mostly those that involved guns, who have enrolled in the program.
Intervention program manager Britney Brown said a victim of violence who is seen at a hospital has a one in four chance of becoming a victim again.
'We're seeing a lot of folks that have issues with conflict mediation,' Brown said. 'There are small conflicts that grow larger due to social media, lack of mental health services, frustration, and there's a lot of easy access to weapons right now.'
The program also tracks enrolled individuals at the 90-day mark.
According to staff, 80% of them have not interacted with the justice system after joining the violence intervention program and more than half are not returning to the hospital as a victim for the second time, Brown said.
Medical professionals said there is still more work to be done to combat youth violence despite the program's positive results.
'We want to have 24-hour coverage,' Brown said. 'As we know, violence is not reducing in the city just yet, and so we need more hands-on-deck. And I think this is something, once we move out of intervention, to be preventative as well.'
The Mecklenburg County Health Department and medical professionals from Atrium Health will use the next 45 days to look at the crime data, which they plan to present to the city council.
VIDEO: Dispute at home led to quadruple shooting in east Charlotte, police say
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
10 hours ago
- Medscape
OS Data From CARTITUDE-1: A Cure for Myeloma?
CHICAGO — The anticipated release of 5-year overall survival (OS) data from the CARTITUDE-1 trial showed that the use of ciltacabtagene autoleucel (cilta-cel) in patients with relapsed or refractory multiple myeloma (RRMM) met or exceeded expectations. 'We already knew from our initial publication that 98% of patients who got cilta-cel responded to therapy and that the majority of those responses were complete responses. We also knew that the median PFS [progression-free survival] was approximately 34 months, which is unheard of in this patient population,' said study author Peter Voorhees, MD, of Atrium Health/Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, during an oral abstract session at the American Society of Clinical Oncology (ASCO) 2025 annual meeting. 'Today we are sharing that the median OS is just over 5 years, and that one third of the study population has remained progression-free following a single cilta-cel infusion with no maintenance therapy.' These findings were simultaneously published in the Journal of Clinical Oncology . CARTITUDE-1 is a phase 1B/2 trial in which 97 patients with four or more prior lines of treatment for RRMM received cilta-cel. Of these patients, 45 are currently alive and in long-term follow-up in the CARTinue 15-year post-infusion study. This group is further broken down among 32 patients who have remained progression-free since their infusion and 13 patients who had progressive disease and are now in post-progressive disease follow-up. Of the progression-free patients, 12 from a single center with annual minimal residual disease (MRD) testing remain MRD-negative at year 5 or longer. Voorhees noted that long-term remissions were not limited to patients with standard-risk disease. 'Patients with high-risk cytogenetics like del17p, t(14;16) or t(4;14) and those with extramedullary plasmacytomas were equally likely to be progression-free,' he said. The study team also found that patients in long-term remission had more immune-fit drug products and higher effector to target ratios at peak expansion, Voorhees said. The discussant for this study, Krina K. Patel, MD, MSc, of MD Anderson Cancer Center in Houston told attendees that the CARTITUDE-1 OS data were 'phenomenal for these hard-to-treat patients' as she reshared Voorhees' PFS slide showing a plateau extending toward 78 months. 'I do hope this plateau continues forever for these 33% of patients, to the point where we can say it's a true cure,' Patel said. 'But I don't hold my breath because most of my patients do relapse at some point.' Patel also noted the limitation that CARTITUDE-1 is a single-arm study. 'We know there's CARTITUDE-4, so we have randomized data that shows better performance than at least a couple of our standard care options,' she said. 'But it is hard to compare historical controls.' Following this presentation, Voorhees sat down with Medscape Medical News . The following interview has been edited for clarity. Since FDA approval of cilta-cel was based on CARTITUDE-1, the expectation was that longer-term data would also be very good. Why are these long-term OS results from CARTITUDE-1 so important? The median overall survival wound up being just over 5 years, when we would have expected it to be 1 year in a similar population. One third of the patients are alive and in remission, and they've been off therapy for 5 years, which is something we've never seen before. Just as importantly, we're not seeing new safety signals, and the rates of high-grade infection seem to be declining further out from treatment, which is what we would expect with immune recovery. Is it time to start thinking of myeloma as a potentially curable disease? I'm always very cautious when I discuss that. Possibly there may be patients who never relapse, but I am curious to see how these next 5 years play out because if the majority of these patients remain in remission 10 years out from cilta-cel infusion, then I'll be using the word 'cure' less cautiously at that time. We do talk a lot about functional cures in multiple myeloma: For someone newly diagnosed with standard-risk disease, they will get a three or four drug induction therapy, then a transplant followed by maintenance therapy. A lot of these patients will stay in remission well beyond 10 years and they'll pass away at an older age of unrelated causes. What do the new CARTITUDE-1 data do to the paradigm of continuous therapy? The other thing that has made us hesitate about using the word 'cure' in myeloma is the traditional paradigm of continuous treatment. What happens to patients in remission when you stop therapy? Are they in a long-term remission because you're keeping the heat on the disease or are they cured and what you're applying to them continuously is unnecessary? What makes the cilta-cel 5-year data so compelling is that these patients got that single infusion and a third of them are still in remission 5 years later. Your ASCO presentation included a discussion of MRD level at 10−5 vs 10−6. Why is that important here? Currently the best that's available as far as regular clinical practice is concerned is a 10−6 but MRD negativity is often reported at 10−5. But as so many people going through CAR T-cell therapy achieve MRD negativity at 10−5, the 10−6 level of sensitivity seems to be a better way of distinguishing those patients that might be at higher risk for disease progression vs those that are not. You're going to see us transitioning more toward using MRD negativity at 10−6 for our clinical trials going forward. What's ahead for the CARTITUDE research program? The expectation is the earlier you use a highly effective therapy, the better it's going to perform. We have the CARTITUDE-4 study, which compares cilta-cel with standard of care in both standard-risk and high-risk disease. CARTITUDE-5 and CARTITUDE-6 are both phase 3 studies looking at the application of cilta-cel therapy for newly diagnosed myeloma patients. For CARTITUDE-5, we're looking to see if adding cilta-cel after lenalidomide, bortezomib and dexamethasone will improve outcomes for patients not eligible to receive an upfront transplant. And in CARTITUDE-6, we're looking to see if cilta-cel can be used instead of autologous stem cell transplantation as consolidation for younger, fitter patients with newly diagnosed myeloma. And if things go the way we expect them to, we may be starting to use that word cure more often. When did it really hit you that the cilta-cel data are better than anything else that has yet happened? We've got several patients from CARTITUDE-1 at our institution who are still in complete remission, and they've lived a normal life for years now. We have patients on the CARTITUDE-2 program who are also long-term responders, so we see this in our everyday practice more and more. If you had told me 10 years ago that this is what we would be doing, I would've thought there's no way. But here we are doing it. This study was funded by Johson & Johnson and Legend Biotech. Voorhees disclosed having relationships with Abbvie/Genentech, Ascentage Pharma, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Indapta Therapeutics, Janssen, Kite (a Gilead company), Nektar, Pfizer, Regeneron, Sanofi, and TeneoBio. Patel reported ties with Abbvie, AstraZeneca, Bristol-Myers Squibb, Celgene, Janssen, Legend Biotech, Merck, Novartis, Pfizer, Regeneron, and Takeda.
Yahoo
5 days ago
- Yahoo
AstraZeneca sues Utah attorney general over new drug pricing law
AstraZeneca, a major pharmaceutical company, has sued Utah's Attorney General Derek Brown over a recently passed state law allowing for lower pricing in pharmacies. The lawsuit concerns how SB69, passed during the 2025 state legislative session, deals with Section 340B of the federal Public Health Service Act. The suit was filed in May in the U.S. District Court of the District of Utah. The lawsuit argues that SB69 violates federal law by expanding the 340B drug discount program to unlimited pharmacies. The 340B drug discount program is designed to provide pricing benefits to specific eligible health care entities. It requires pharmaceutical manufacturers to offer products at steeply discounted rates for a specific list of entities. 'Because such price controls can disincentivize innovation and destabilize markets, Congress carefully crafted Section 340B and limited participation in the program to fifteen — and only fifteen — types of covered entities," per the lawsuit. It also points out that for-profit pharmacy chains, such as CVS and Walgreens, were not included in the list of covered entities. AstraZeneca's suit seeks for an order declaring that SB69 violates federal law and is unconstitutional. It also seeks to stop Brown and Utah Insurance Commissioner Jon Pike from enforcing SB69 against AstraZeneca in any manner. The Utah Attorney General's Office said Friday it had no comment on the lawsuit. SB69, which was sponsored by Sen. Evan Vickers, R-Cedar City, defines terms related to the 340B drug discount program and prohibits pharmaceutical manufacturers from setting certain restrictions. Under the law, manufacturers cannot prohibit or restrict pharmacies from contracting with 340B entities. They also cannot deny these 340B entities access to specific drugs. 'Apparently dissatisfied with the scope of federal law, the State of Utah has enacted a statute seeking to achieve under state law precisely the same result that federal courts have resoundingly rejected,' per the suit. 'The state law requires pharmaceutical manufacturers to offer 340B-discounted pricing for sales at an unlimited number of contract pharmacies.' The suit says that SB69 extends Section 340B price caps beyond the scope of the federal program, requiring manufacturers to make discounted drugs available for sale at any and all pharmacies 'authorized by a 340B entity to receive the drug.' It alleges that the law extends the discounts to new categories of transactions that are not covered by the program, thus conflicting with federal law requirements. The suit argues that the law conflicts with federal law, specifically court rulings that 'make clear that the federal 340B statute does not obligate manufacturers to deliver discounted drugs to unlimited contract pharmacies." According to the suit, SB69 also violates federal patent law, which 'prohibits states from regulating the price of patented goods.' 'It requires manufacturers like AstraZeneca to offer steeply discounted prices for the sale of their patented drugs, thereby extending federal price caps to an additional category of patented drug sales (contract pharmacy sales) that federal courts have held fall outside of the 340B program. It also argues that SB69 violates the Contracts Clause of the U.S. Constitution and the Constitution's takings clause.
6 days ago
Dietitian Rachel Beller shares recipes and tips to spice up your summer travel
Summer travel just got a flavorful and healthy boost! With a few smart tips -- and a dash of spice -- you can stay on track with your wellness goals while still enjoying every moment on the go. Rachel Beller, registered dietitian and bestselling author of "SpiceRack," stopped by "Good Morning America" and "GMA3" on Thursday to share easy, practical ways to elevate your travel routine and keep your energy up wherever your journey takes you. Scroll down for her expert tips and delicious recipes. 1. Packable Morning Boost Bowl Easy, budget-friendly travel breakfast. "How we start our day has a huge impact on how we feel and I have something that is both nourishing and budget-friendly that you can easily travel with… Morning boost Power Pack -- helps to deliver protein, fiber, and lots of antioxidants -- no kitchen required! Throw a few packets in your suitcase," Beller said. How-to: Pack individual dry servings before your trip. At your destination, just add milk or yogurt. Top with either dry or fresh seasonal local fruit. Sprouted Oats: Rich in beta-glucans to nourish your gut microbiome, support your digestion, and immune health Ground Flax Seeds: Packed with fiber and omega-3s; supports regularity and helps maintain blood sugar balance Morning Boost Spice Blend: Features Ceylon cinnamon, allspice, ginger, nutmeg, and clove -- a naturally sweet combo that is rich in antioxidants and anti-inflammatory properties Walnuts: Crunchy and satisfying; provide plant-based omega-3 fats and protein to help keep you full Hemp Hearts or Pumpkin Seed Protein Powder: A simple protein source rich in iron and magnesium to support energy Demo Visual: Stainless steel or travel jar filled with dry ingredients, small container of milk/yogurt, fresh or dried fruit. Include eco-friendly pouches. Recipe (Single-Serve): ½ cup sprouted oats 1 tbsp ground flax ½ tsp Morning Boost spice blend 1 tbsp hemp hearts or pumpkin seed protein powder 2 tbsp crushed walnuts Destination add-ins: Milk or yogurt, fresh fruit like berries or peaches or dried fruit. Perhaps a drizzle of honey or date syrup (optional?) 2. Hydrate with Intention: Mint & Ginger Infused Water Refreshing morning ritual before coffee or after a workout. "What we drink while we travel can also get upgraded to support digestion and hydration," Beller said. "It's very easy to grab some fresh mint leaves and ginger at the produce section at a grocery store. Most hotels offer a tea kettle." Ingredient highlights: Mint: Naturally soothing for the digestive system; may help relax digestive muscles and reduce bloat. The aroma can be nice and calming. Ginger: Contains gingerol, known for its anti-inflammatory and digestive-supportive properties, as well as its ability to help ease muscle soreness after a workout. 1 cup hot water 1 handful fresh mint leaves (or 1 tsp dried or a mint tea bag) 1 slice fresh ginger root (or a ginger tea bag or dried ginger pieces) Steep 3–4 minutes. Enjoy hot, warm, or chilled after your morning workout at your hotel. Optional: If option for dry–pack a tiny tea infuser to steep dried herbs easily wherever you are. 3. Smart, Packable Snacks "How we snack while we travel is important," Beller said. "We often find ourselves scrambling for something quick, which usually leads to highly processed options filled with unnecessary additives and added sugars -- things that can throw off our energy balance and health goals." She continued, "My patients always tell me how much they love having simple snack solutions on hand. It makes them feel empowered knowing they're supporting their energy, digestion, and immune system." Power Snack Line-up 1. Berry Crunch Kamut Mix (light, easy to carry) Puffed Kamut: A fun, crunchy puffed whole grain that's fun to eat (think popcorn) Freeze-Dried Strawberries: Packed with antioxidants and vitamin C Slivered Almonds: contains healthy fats, protein, and vitamin E Cacao Nibs: a hint of chocolatey crunch (optional) 2. Golden Carrot Coins with spiced Hummus (my favorite flight snack) Carrot Coins: Rich in beta-carotene and fiber; filling and satisfying Mini Hummus Container: Great source of plant protein, fiber, and healthy fats Sumac: A tangy, citrusy spice that may aid digestion by promoting the release of digestive enzymes; perfect for summer flavor and gut support 3. Tropical Power Crunch (crunchy and chewy- great for a hike, beach, etc) Roasted Dried Chickpeas (store bought or roasted at home with a touch of spice): High in plant-based protein and fiber; supports fullness and blood sugar stability Dried Mango or Pineapple (no added sugar): Offers fiber, vitamin C, and natural sweetness Cinnamon: Adds a touch of sweetness and antioxidants and may help support blood sugar balance 4. "Keep Me Regular" Power Bites (stuff the dried plums with 2-3 nuts -- a travel essential that not only tastes sweet and delicious -- it helps keep things moving!) Dried Plums: High in both soluble and insoluble to help regulate digestion, which is especially useful during travel. Plums are rich in vitamin C and polyphenols -- compounds with antioxidant properties that support our immune function. Baru Nuts or Hazelnuts: Rich in healthy fats, protein, and fiber for sustained energy Cinnamon: Adds a touch of sweetness and antioxidants and may help support blood sugar balance Packaging tips: Use light steel or eco-friendly bags or small glass containers that are very portable. 'GMA' kitchen picks By clicking on these shopping links, visitors will leave and and these e-commerce sites are operated under different terms and privacy policies. ABC will receive a commission for purchases made through these links. SOME PRICES ARE DYNAMIC AND MAY CHANGE FROM THE DATE OF PUBLICATION. Have questions about ordering or a purchase? Click here. Amazon
